Abstract
Epsilon-aminocaproic acid (EACA) is a potent anti-fibrinolytic agent that is used in the treatment of excessive bleeding resulting from a systemic fibrinolytic state. It can also be used to treat hematuria through its action on decreasing urinary fibrinolysis. A broad range of renal complications has been ascribed to EACA. Although they are rare, they may be life-threatening and should therefore be immediately recognized.
MeSH terms
-
Acute Kidney Injury / chemically induced*
-
Aged
-
Aminocaproic Acid / adverse effects*
-
Aminocaproic Acid / therapeutic use
-
Antifibrinolytic Agents / adverse effects*
-
Antifibrinolytic Agents / therapeutic use
-
Creatinine / blood
-
Female
-
Hematuria
-
Humans
-
Hydronephrosis / diagnostic imaging
-
Hydronephrosis / etiology
-
Kidney / diagnostic imaging
-
Nephrostomy, Percutaneous
-
Radiography
-
Thrombosis / drug therapy
-
Ultrasonography
Substances
-
Antifibrinolytic Agents
-
Creatinine
-
Aminocaproic Acid